# FDA approves first factor XIa inhibitor for secondary stroke prevention

Source: [Medical Xpress - latest medical and health news stories](https://medicalxpress.com/news/2026-11-fda-factor-xia-inhibitor-secondary.html) · 2026-11-18 · Medicine
Page: https://themorning.science/story/fda-approves-first-factor-xia-inhibitor-for-secondary-stroke-prevention-e079628937f73998
Kind: release · Impact: medium

## In brief

- The FDA approved Sunharbo (asundexian) 50 mg tablets, taken with antiplatelet therapy, to reduce stroke risk in adults.
- The approval covers adults after a recent mild-to-moderate noncardioembolic ischemic stroke or a high-risk transient ischemic attack.
- Asundexian is described as the first factor XIa inhibitor approved by the FDA for secondary stroke prevention.

## Why it matters

It adds a new anticoagulant-class drug targeting factor XIa for preventing a second stroke, a population with high recurrence risk, giving clinicians a new option alongside antiplatelet therapy.

## Timeline

- 2026-11-18: FDA approval of Sunharbo (asundexian) 50 mg tablets for secondary stroke prevention reported by Medical Xpress

## Coverage

- [FDA approves first factor XIa inhibitor for secondary stroke prevention](https://medicalxpress.com/news/2026-11-fda-factor-xia-inhibitor-secondary.html) — Medical Xpress - latest medical and health news stories, 2026-11-18

Tags: stroke prevention, factor xia inhibitor, asundexian, fda approval, anticoagulation

---

Brief generated by AI (claude-haiku-5-5) from the reporting listed under Coverage. Headlines belong to their publishers. The Morning Science – https://themorning.science
